Spruce Biosciences, Inc. (SPRB)
Stock Price:
$16.92 USD
0.11 (0.65%)
Updated Oct 21, 2020 3:59 PM EDT - Market closed
Key Info
| Market Cap |
392.01M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-17.35M |
| Shares Out |
22.26M |
| EPS (ttm) |
-0.78 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$16.92 |
| Previous Close |
$16.81 |
| Change ($) |
0.11 |
| Change (%) |
0.65% |
| Day's Open |
16.91 |
| Day's Range |
16.09 - 17.00 |
| Day's Volume |
163,706 |
| 52-Week Range |
15.12 - 18.49 |
More Stats
| Market Cap |
392.01M |
| Enterprise Value |
359.65M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
22.26M |
| Float |
19.08M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.78 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
12.14 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
-17.35M |
| Free Cash Flow |
n/a |
| Net Cash |
32.35M |
| Net Cash / Share |
1.40 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -13.11 | -9.97 |
| Net Income | -13.09 | -9.86 |
| Shares Outstanding | 5.00 | 4.91 |
| Earnings Per Share | -2.62 | -2.01 |
| Operating Cash Flow | -12.62 | -8.57 |
| Capital Expenditures | - | - |
| Free Cash Flow | -12.62 | -8.57 |
| Cash & Equivalents | 3.92 | 4.11 |
| Total Debt | 4.45 | - |
| Net Cash / Debt | -0.52 | 4.11 |
| Assets | 4.69 | 4.78 |
| Liabilities | 7.52 | 2.71 |
| Book Value | -30.64 | -17.80 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Spruce Biosciences, Inc. |
| Country |
United States |
| Employees |
15 |
| CEO |
Richard A. King |
Stock Information
| Ticker Symbol |
SPRB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SPRB |
| IPO Date |
October 9, 2020 |
Description
Spruce Biosciences, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.